🇬🇧 Cancer in the United Kingdom

GLOBOCAN 2022 estimates 454,954 new cancers and 181,807 cancer deaths a year in the United Kingdom, an age-standardised incidence of 307.8 per 100,000 and an age-standardised mortality of 98.3, with a cumulative risk of a diagnosis before 75 of 29.7 percent. Set the mortality rate beside the incidence rate and the United Kingdom's ratio is about 0.32, against 0.22 for the United States, 0.19 for Australia, 0.26 for Canada and 0.28 for Sweden; the table below this section does that arithmetic country by country from one source. The National Cancer Plan for England, published on 4 February 2026, states it in words: "Cancer mortality rates in the UK are much higher than in other, comparable countries, while survival is lower. Early diagnosis rates were flat for nearly a decade beginning in 2013 and have only recently started to increase." About 2.4 million people in England are living with or beyond a cancer diagnosis; Cancer Research UK counts 403,601 new cancer cases a year across the United Kingdom, averaging 2019 with 2021 and 2022.

The national cancer registration dataset in England has had "national coverage since 1971" and receives about 25 million records a year for roughly 300,000 malignant tumours. Its legal basis is section 251 of the National Health Service Act 2006, implemented through regulation 2 of the Health Service (Control of Patient Information) Regulations 2002, a regulation whose heading is literally "Medical purposes related to the diagnosis or treatment of neoplasia": cancer is the one disease with its own consent exemption. The quality indicator that travels internationally is the death-certificate-only rate, which fell from more than 8 percent of cancers in the 1980s to under 1 percent of registrations by 2016; the Office for National Statistics estimated 2017 registrations at 98.5 percent complete. The service moved from Public Health England to NHS Digital on 1 October 2021 and is now part of NHS England. The Simulacrum, built by Health Data Insight with AstraZeneca and IQVIA, is a synthetic copy of it, version 2.1.0 covering diagnosis years 2016 to 2019 with tumour, systemic therapy, radiotherapy and gene-testing tables, free to download and analyse without a permission or a confidentiality risk. Scotland, Wales and Northern Ireland publish separately, and what each publishes differs, which the four-nations section sets out.

The National Cancer Plan for England puts it at "as many as a third of cancers are preventable", with tobacco, diet, obesity, alcohol and ultraviolet exposure as the key risk factors, and names over-exposure to ultraviolet radiation as the third highest preventable cause after tobacco and overweight and obesity. The per-cancer pages on this site carry the shape: Cancer Research UK attributes 72 percent of UK lung cancer cases and 86 percent of lung cancer deaths to smoking, 86 percent of melanomas to ultraviolet overexposure, 54 percent of bowel cancers and 37 percent of pancreatic cancers to preventable causes. Lung cancer mortality is 102 percent higher in women and 93 percent higher in men in the most deprived fifth of the population than in the least, and the plan states that lung cancer alone accounts for almost a year of the nine-year life expectancy gap between richer and poorer parts of England. The gradient runs through diagnosis too: in the twelve months to September 2025, 56.0 percent of cancers in England's most deprived quintile were found at stage 1 or 2, against 62.2 percent in the least deprived, a gap that has narrowed from 8.2 percentage points before the pandemic to 6.2.

Health was never reserved: the Scotland Act 1998 reserves medicines, poisons, embryology and xenotransplantation but not the health service itself, and the equivalent Welsh reservations now sit in Schedule 7A, in force since 1 April 2018. Health functions transferred to the National Assembly for Wales on 1 July 1999, to the Scottish Parliament on the same principal appointed day, and to Northern Ireland on devolution day, 2 December 1999. Northern Ireland's integration is not a habit but a statutory duty: section 2(1) of the Health and Social Care (Reform) Act (Northern Ireland) 2009 requires the Department to "promote in Northern Ireland an integrated system of health care and social care", delivered through five Health and Social Care trusts. What remains United Kingdom-wide is short: the Medicines and Healthcare products Regulatory Agency licenses a medicine for the whole country, the UK National Screening Committee advises all four governments and is accountable to their four chief medical officers, and general taxation pays for it under a Barnett formula whose Department of Health and Social Care comparability factor is 99.5 percent. Almost everything a patient meets is devolved. A sentence beginning "in the UK" is usually wrong about at least one nation, and the cards below say which.

England has three standards: 28 days from an urgent suspected cancer referral, an urgent screening referral or a consultant upgrade to the day the patient is told (the Faster Diagnosis Standard, raised to 80 percent from the first quarter of 2026/27), 31 days from the decision to treat to the first treatment (96 percent), and 62 days from referral to first treatment (85 percent). In July 2026 it achieved 79.3, 92.5 and 71.2 percent, with 9,091 people treated outside 62 days in that month alone. Scotland has two standards, both set at 95 percent, 31 days from decision to treat and 62 days from an urgent suspicion of cancer referral; in the quarter to 31 March 2026 it achieved 94.5 and 72.2 percent, and the 62-day standard was met by no NHS board. Wales replaced separate standards with a Single Suspected Cancer Pathway measured from the point of suspicion, with a 75 percent target at 62 days; in July 2026 it achieved 60.1 percent, from 44.7 percent in Swansea Bay to 67.5 percent in Cwm Taf Morgannwg. Northern Ireland sets 98 percent at 31 days and 95 percent at 62 days, plus a 14-day target for urgent breast referrals to be seen; in the quarter to 31 March 2026 it achieved 87.3 percent, 29.6 percent and 7.9 percent. The 62-day figure was withheld at first and the whole series republished on 11 September 2026 after an error in the suspension logic of its new encompass patient administration system, which revised every quarter back to December 2024 downward by as much as 4.5 percentage points. Even within one nation the clock differs by cancer: England stops the 62-day clock for a man with lower-risk prostate cancer when active monitoring is agreed, counting that as a first treatment, and neither the Scottish nor the Welsh publication says whether it does the same.

England's cancer waiting times monitoring dataset guidance applies the treatment standards to ICD-10 C00 to C97 excluding basal cell carcinoma of skin, and to D05. Section 5.10 puts C43 and C44 in scope, then names seven excluded conditions (basal cell carcinoma and its multicentric, morphoeic and fibroepithelial variants, basosquamous carcinoma, metatypical carcinoma and pilomatrix carcinoma) and puts lentigo maligna, Bowen's disease, intraepidermal carcinoma and keratoacanthoma out of scope as carcinoma in situ or benign; cutaneous squamous cell carcinoma and Merkel cell carcinoma are in. Public Health Scotland's inclusion criteria for the same standards read, for skin, "melanoma, new primary invasive (i.e. Clark level greater than 1, melanoma of any site except eye); includes C43": C44 does not appear on the list at all. Northern Ireland's ICD-10 mapping maps both C43 and C44 to a Skin Cancers tumour site and labels C44 explicitly as other malignant neoplasms of skin except basal cell carcinoma, which is England's rule. Wales reports one all-cancer pathway with no site split. This is not a technicality: it decides whether a real person's wait is counted at all, and it is invisible in every headline that compares the four nations.

The asymmetry runs both ways. Scotland is the only nation that publishes a lung-specific waiting-time split, and the only one with a breast or prostate split at health board level; Public Health Scotland's open data gives incidence to 2024, mortality to 2024, survival to 2022 and staging with deprivation breakdowns in downloadable workbooks, which for lung cancer is the most complete public data of the four nations. Against that, Scotland publishes no gallbladder (C23) or extrahepatic bile duct (C24) site at all: its open data and Table 1 spreadsheets carry liver and intrahepatic bile ducts (C22) and pancreas (C25) only, so a Scottish gallbladder cancer figure does not exist in public. The Northern Ireland Cancer Registry assigns a stage to 94.7 percent of lung cancers, the best stage completeness of the four nations. England's National Disease Registration Service publishes the largest and deepest dataset of the four, including routes to diagnosis, and answers HTTP 403 to automated readers, which is why several England figures across this site are quoted from Cancer Research UK, which builds on the same registrations, or from the government's own cancer plan, rather than from the registry itself.

Bowel screening: England, Scotland and Wales invite people aged 50 to 74 every two years with a faecal immunochemical test; Northern Ireland invites from 60 to 74 and is, on the Northern Ireland Assembly's own account, still considering lowering it. Scotland went further in the other direction on 12 July 2026, when its public health minister asked the UK National Screening Committee to review the recommended starting age, citing a 49 percent rise in colorectal cancer in people under 50 between 2013 and 2023, and said Scotland would pilot alone if the committee declined. Cervical screening: England moved to a five-year interval for the whole 25 to 64 range on 1 July 2025, having followed Wales, which did so on 1 January 2022, and Scotland; Northern Ireland still invites women aged 25 to 49 every three years and 50 to 64 every five. Breast screening: 50 to 70 in Scotland and Northern Ireland, 50 up to the 71st birthday in England, where the AgeX trial of an extra screen at 47 to 49 and at 71 to 73 remains a trial and not routine practice. Lung screening is being rolled out in England with a target of full national coverage by March 2030; the other nations are at different stages.

Principle 2 of the NHS Constitution reads: "Access to NHS services is based on clinical need, not an individual's ability to pay. NHS services are free of charge, except in limited circumstances sanctioned by Parliament." The distinction that catches people out is between health care, which is free, and social care, which is means-tested: a person who needs help washing and dressing after treatment is in the social care system unless their needs are judged primarily health needs, when NHS Continuing Healthcare pays. Free hospital car parking for frequent outpatient attenders, including cancer patients, has been required in England since 1 January 2021 through the NHS Standard Contract, and has applied in non-private-finance hospitals in Scotland since 2008; Northern Ireland legislated to abolish charges in 2022 and has not commenced the Act, most recently postponing it to a date no later than 12 May 2029, so parking charges there remain lawful. Two routes to exemption from prescription, dental and optical charges have just been removed: the tax-credit route ended on 23 June 2025 as tax credits ended, and legacy Department for Work and Pensions benefits ceased to qualify from 1 April 2026, with a time-limited discretion under the Low Income Scheme expiring on 1 April 2027. The residency rule is worth stating plainly: the NHS is residency-based, so a UK national who moves abroad permanently loses entitlement to free NHS care, and an overseas visitor who is charged pays 150 percent of the national tariff.

The cancer exemption was created by the National Health Service (Charges for Drugs and Appliances) (Amendment) Regulations 2009, made on 13 January 2009 and applying to drugs supplied on or after 1 April 2009, covering a person "undergoing treatment for cancer, the effects of cancer, or the effects of cancer treatment" and claimed on form FP92A. The current English charge of 9.90 pounds an item was set by regulations in force on 1 May 2024 and has not been raised since; everyone aged 60 and over is exempt, which covers most people with the commonest cancers, and prepayment certificates cap the cost for those who are not. Scotland abolished the charge in 2011, Wales in 2007 and Northern Ireland in 2010, so in those three nations there is nothing to apply for; Wales issues a WP92A certificate and Scotland an EC92A for people who need a prescription dispensed in another nation. This is the clearest small example of the four-nations pattern: the same diagnosis, the same drug, four different answers to what it costs at the counter.

The change followed Professor Mike Richards's review, published on 4 November 2008, which found "a great deal of confusion about the rules in this area" and that "many patients were not clear whether they would still be entitled to NHS care if they purchased additional private drugs". The Department of Health guidance that followed states at paragraph 4.1 that "where a patient opts to pay for private care, their entitlement to NHS services remains and may not be withdrawn", and its executive summary lists four rules: NHS organisations should not withdraw NHS care simply because a patient chooses to buy additional private care; any additional private care must be delivered separately; the NHS must never charge for NHS care and should never subsidise private care; and the NHS should continue to provide free of charge all care the patient would have been entitled to anyway. Paragraph 4.2 defines separation as a different time and a different place, which can be a private provider, a private wing, an amenity bed or a room temporarily designated for private care; paragraph 4.3 allows departure only for overriding patient safety reasons, not convenience. The guidance is England-only, came into force on 23 March 2009 and does not apply retrospectively.

The MHRA has been the sole United Kingdom regulator since 1 January 2021. Its European reliance routes ended on 31 December 2023 and were replaced on 1 January 2024 by the International Recognition Procedure, a 60-day or 110-day route that relies on a prior approval by the regulators of Australia, Canada, the European Union, Japan, Switzerland, Singapore or the United States; the national route runs to 150 or 210 days. In 2025/26 the agency approved 921 medicinal products including 39 new medicines. Then the payers: NICE for England, whose recommendation carries a statutory funding requirement under regulation 7 of the 2013 NICE Constitution and Functions Regulations, which gives commissioners three months, or 30 days for products in the Early Access to Medicines Scheme or a fast-track appraisal. Scotland decides for itself through the Scottish Medicines Consortium, which sits inside Healthcare Improvement Scotland and has advised on more than 2,000 medicines since 2002; in 2024/25 it published 96 pieces of advice, accepting 66 percent. Wales adopts NICE and its All Wales Medicines Strategy Group appraises only what NICE has not, with the New Treatment Fund requiring health boards to fund a recommended medicine within 60 days. Northern Ireland's Department of Health reviews each NICE appraisal for legal, policy and financial consequences within four weeks of final publication, issues a service notification within fifteen weeks of endorsement and expects implementation within three months; where NICE has not looked at a treatment, Northern Ireland considers adopting the Scottish and then the Welsh decision, in that order. From 1 April 2026 the MHRA and NICE run an aligned pathway intended to bring some English decisions three to six months forward.

NICE's own figures, read from its cancer appraisal data page: "Since 2000, we have published: 596 technology appraisals on cancer drugs. These have resulted in: 666 individual recommendations", of which "83% of our recommendations on cancer drugs have been positive". Then, under a heading reading "Not included in the data": "Recommendations could not be made for 100 technology appraisals in the absence of a submission from the company (known as a non-submission)." A hundred cancer appraisals that never happened are counted separately from the 666 that did, which is the distinction in a single sentence. A refusal is a decision: NICE TA580 refused enzalutamide for high-risk hormone-relapsed non-metastatic prostate cancer on 15 May 2019 because "the estimates are not within the range that NICE usually considers a cost-effective use of NHS resources". A termination is the absence of one: NICE's wording is "NICE is unable to make a recommendation ... This is because the company did not provide an evidence submission", and terminated appraisals sit at a different address, nice.org.uk/guidance/terminated/, which is how a machine can tell them apart. Process manual PMG36 adds a nuance worth knowing: at 5.6.9 NICE will consider terminating if no submission arrives, but at 5.6.12 it "may also use the termination process to manage a company submission with a significantly high ICER", and at 5.6.13 a termination can be restarted, so the individual guidance page is the only reliable evidence of which happened. Scotland does the opposite with the same facts: rather than terminate, the Scottish Medicines Consortium issues substantive negative advice anyway, printing "Advice in the absence of a submission from the holder of the marketing authorisation: [medicine] is not recommended for use within NHSScotland", and its April 2025 process document confirms this does not prevent a later submission, which would supersede the advice. The third case has no page at all, but for cancer in England the gap is largely closed: since the 2016 Cancer Drugs Fund reforms "all new cancer drugs and significant new licensed indications for cancer drugs are now referred automatically to NICE for appraisal". Where a medicine falls outside that, as sonidegib does for locally advanced basal cell carcinoma, there is no decision to find, and the NHS Constitution's answer is a different right: a right to expect a local decision made rationally on the evidence, rather than a right to the drug.

The original Cancer Drugs Fund ran from October 2010 with a lifetime budget of 1.27 billion pounds and supported over 74,000 patients to March 2015. The National Audit Office's investigation of 17 September 2015 found that 51 percent of the patients supported between April 2013 and March 2015 received drugs NICE had appraised and not recommended, that the fund overspent its allocated budget by 35 percent across those two years, and, most damningly, that "due to a lack of data, it is not possible to evaluate the impact that the Fund has had on patient outcomes, such as survival". NHS England's own account records a 2015/16 outturn of 466 million pounds against 340 million, a 37 percent overspend, and the board's decision on 26 February 2016 to rebuild it. The new fund began on 29 July 2016 with a fixed 340 million pound annual budget, an expenditure control mechanism that claws back overspend, and a third NICE outcome, "recommended for use within the Cancer Drugs Fund", available where NICE sees "plausible potential" but "significant remaining clinical uncertainty". A managed access agreement runs for at most five years, after which a full reappraisal decides whether the drug moves to routine commissioning. NICE has made 61 Cancer Drugs Fund recommendations since 2016; 14 cancer medicines are in managed access now. The sister Innovative Medicines Fund, launched in June 2022 with an identical 340 million pound budget, is for non-cancer medicines only, and is barely used by comparison: NICE has made three Innovative Medicines Fund recommendations in its history against 61 for cancer.

Across the full study, 148 SMC and 161 NICE oncology appraisals published between 1 January 2017 and 31 December 2022, the two bodies recommended almost identically, 90.5 percent of SMC decisions positive against 89.4 percent of NICE's. The real difference was speed, and only for solid tumours: a median 291 days from marketing authorisation to guidance for the SMC against 257 for NICE overall, which did not reach significance, but 273 against 231.5 days for solid organ cancers, which did. The author attributes the gap in part to the Cancer Drugs Fund. On the individual route, England's individual funding request still turns on "clinical exceptionality", meaning a clinician must show the patient is in a different clinical condition from the typical patient with the same disease. Wales abolished that test after a 2017 review and its individual patient funding request panels now ask instead whether significant clinical benefit is expected for that patient and whether the cost is in balance with it. Scotland replaced individual patient treatment requests in February 2018 with the Peer Approved Clinical System, whose tier two guidance was announced with the striking instruction that "a decision for non-routine access must not include cost-effectiveness as part of the consideration", alongside a separate ultra-orphan pathway introduced in October 2018 for conditions affecting one person in 50,000 or fewer, which funds for up to three years while data are gathered. Northern Ireland runs individual funding requests through a regional scrutiny committee, and its endorsement circular is explicit that a patient already on a drug NICE later refuses "should have the option of continuing their therapy until they and their clinicians consider it appropriate to stop".

ProtecT PSA-tested 82,429 men aged 50 to 69 across nine UK centres, randomised 1,643 between active monitoring, surgery and radiotherapy, and found no significant difference in prostate cancer death at ten years or at fifteen. CHHiP took 3,216 men at 71 centres from 37 fractions to 20 and PACE-B took a subgroup to five; START-B and FAST-Forward did the same for breast radiotherapy, from 25 fractions to 15 and then to five in a week. QUASAR randomised 3,239 people whose need for adjuvant chemotherapy was genuinely unclear and turned a default into a 3.6 percent absolute five-year survival gain a patient could weigh; SCOT then showed three months was enough where six had been standard. MRC CR07 cut three-year local recurrence in rectal cancer from 10.6 percent to 4.4 percent with a week of preoperative radiotherapy. MRC COIN showed cetuximab added nothing to oxaliplatin-based chemotherapy even in KRAS wild-type bowel cancer. SINS asked whether a cream could replace the knife for basal cell carcinoma and answered no; MoleMate tested a diagnostic gadget for GPs and stopped the NHS buying one. STAMPEDE, which ran one shared control arm against ten questions and recruited nearly 12,000 men between 2005 and 2023, won an inaugural NIHR Impact Prize in March 2025 with an estimated one million life years gained globally. The infrastructure is the National Institute for Health and Care Research, through which the Department of Health and Social Care invested 1.6 billion pounds in domestic research in 2024/25, the 50 UKCRC-registered clinical trials units, 29 Experimental Cancer Medicine Centres, and Cancer Research UK, which spent 416 million pounds on research in the year to 31 March 2026, supports more than 100 clinical trials open to more than 80,000 people, and describes itself as the world's largest non-commercial, non-governmental funder of cancer research.

The audits are why several figures on this site exist at all, and why some of them move. The bowel audit's 2025 report shows minimally invasive major colorectal cancer surgery rising from 66 percent in 2019 to 75 percent in 2023, adjusted 90-day mortality after major resection falling from 3.1 to 2.5 percent, and diagnosis at stage 1 or 2 rising from 39 to 42 percent. The lung audit's 2026 report shows the surgical resection rate in non-small-cell lung cancer rising from 18 percent in 2022 to 22 percent in 2024, stage 1 to 2 diagnosis from 32 to 40 percent, one-year survival from 45 to 51 percent and median survival from 281 to 372 days. The coverage is two nations, not four: Scotland and Northern Ireland are not in the audits and publish quality performance indicators and registry reports instead, and Welsh data quality is currently affected by a cancer informatics implementation, with quarterly Welsh data not expected until 2027. The audits are also candid about what they do not measure: the bowel audit publishes no time-to-treatment indicator, and the prostate audit publishes no active surveillance uptake figure and no patient-reported outcomes in its 2025 report. Note the granularity carefully: NATCAN reports at trust and alliance level and "do not routinely report hospital-level results".

The 100,000 Genomes Project was announced on 10 December 2012 and reached its target in December 2018, with more than 85,000 participants; its cancer arm produced an integrated analysis of 13,880 solid tumours across 33 cancer types, published in Nature Medicine in January 2024, finding small variants in 94 percent of glioblastomas, actionable structural variants in 13 percent of sarcomas and homologous recombination deficiency in 40 percent of high-grade serous ovarian cancers. Genomics England's Cancer 2.0 programme is now testing long-read sequencing and multimodal data that joins genomics to pathology and radiology images. The service side is where the difficulty shows. A survey of 21 UK neuro-oncology centres covering about 84 percent of the population found the share requesting whole genome sequencing rising from 4 of 21 in 2021 to 15 of 21 in 2024, and 19 of 21 snap-freezing brain tumour samples in 2024, but at a mean of 173 samples per centre with a range from 0 to 650: one centre in ten could not freeze tumour at all. Turnaround worsened over the same period, from a mean 16 days to 21, and the share of centres meeting a 14-day target fell from 48 percent to 30. A West Midlands series of 146 gliomas sequenced as NHS standard of care found the median time from sampling to report falling from 255 days in early 2022 to 137 days by late 2023, with 17.8 percent producing a trial recommendation. What the four nations do not share is the directory: Scotland, Wales and Northern Ireland each run their own genomics service.

The committee's recommendations are published with the evidence behind them, so a reader can find out why a cancer is not screened for rather than only that it is not. Its prostate work is live: a twelve-week public consultation closed on 24 February 2026, and the modelling behind it found that around 40 to 50 percent of screen-detected cancers are slow growing and that at age 60 roughly half of screen-detected cases would be overdiagnosed, while the evidence on Black men was too thin to decide. TRANSFORM, designed with the committee's input, invites Black men from 45 against 50 for everyone else and carries a floor of at least one in ten invitations going to Black men. NHS-Galleri took the same approach to a commercial multi-cancer blood test: 142,250 people randomised in England from September 2021, with the primary endpoint of fewer stage III and IV diagnoses not met, full results at ASCO in mid-2026 and the test-performance paper in Nature Medicine on 22 September 2026. Britain is unusual in running a randomised trial of a screening product at that scale and publishing that it did not work. The HPV evidence runs the other way: Falcaro and colleagues showed in the Lancet in 2021 that girls offered the bivalent vaccine at 12 or 13 had 87 percent fewer cervical cancers and 97 percent fewer CIN3 lesions than the unvaccinated reference cohort, and the 2026 mortality follow-up found a 100 percent reduction in cervical cancer deaths in women aged 20 to 24 over 2020 to 2024. England's ambition is to eliminate cervical cancer by 2040.

SURVMARK-2 collected patient-level data on 3,764,543 cancers from population-based registries in 19 jurisdictions across Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom, for seven cancer sites diagnosed between 1995 and 2014, and concluded that "for 2010 to 14, survival was generally higher in Australia, Canada, and Norway than in New Zealand, Denmark, Ireland, and the UK". Its own data file gives the five-year age-standardised net survival for the 2010 to 2014 cohort: UK lung 14.8 percent against Canada's 21.7; pancreas 7.9 against Australia's 14.3; colon 59.0 against Australia's 70.8; rectum 62.1 against Australia's 70.8; stomach 20.8 against Australia's 32.8; oesophagus 16.2, sixth of seven; ovary 37.1, fifth. Over the same twenty years UK five-year survival roughly doubled in lung (7.2 to 14.8), pancreas (3.3 to 7.9) and oesophagus (8.6 to 16.2) and rose by more than fourteen points in rectal cancer. The government's own technical annex to the 2026 cancer plan reports England's CONCORD-3 position across 18 cancers as 15th of up to 28 European countries, ranging from 4th for childhood acute lymphoblastic leukaemia and 7th for melanoma to 21st for lung and 22nd for stomach. Both comparisons rest on cohorts ending in 2014; the annex notes that CONCORD-4, covering 2015 to 2019, was expected later in 2026 and should be checked before this page is relied on.

Cancer Research UK's 2025 overview puts early-stage diagnosis at around 55 percent of cancers in England and Northern Ireland, among those with a known stage, and notes that the current trajectory falls far short of the 75 percent ambition; the government's technical annex, working from the Rapid Cancer Registration Dataset rather than full registration, describes the same measure as broadly flat in the mid-fifties and recovering to around 60 percent by mid-2025. The two figures use different datasets with different lags and should not be averaged. On emergency presentation, Cancer Research UK reports 19 to 22 percent across Scotland, Northern Ireland and England, down from around 24 percent in England since 2006, and the technical annex describes it as still the route for a fifth of cancers in 2024. The International Cancer Benchmarking Partnership's own study of 857,068 patients across 14 jurisdictions and eight cancers found that emergency presenters had more than 1.9 times the odds of dying within twelve months in every one of the 112 jurisdiction-by-site strata examined, and that a 10 percent increase in a jurisdiction's emergency-presentation share was associated with a fall in one-year net survival of between 2.5 and 7.0 percentage points. The delay after diagnosis matters too: the largest systematic review of the question, led from Queen's University in Canada with British co-authors, pooled 1,272,681 patients across 17 indications and found that each four-week delay to treatment raised mortality by 6 to 8 percent for surgery and by 1 to 28 percent for systemic treatment.

The plan's wording is that "since 2014, the NHS has consistently missed its central cancer performance target ... it has not met this target at a national level since late 2015"; NHS England's own monthly time series puts the last compliant month at December 2015 on 85.1 percent, with January and February 2016 at 81.0. Performance is now rising slowly: the financial-year figures for the 28-day, 31-day and 62-day standards run 70.2, 91.4 and 64.8 percent in 2022/23; 72.8, 90.1 and 64.7 in 2023/24; 76.4, 91.1 and 68.5 in 2024/25; 76.3, 91.8 and 69.4 in 2025/26; and 78.3, 92.2 and 70.2 in 2026/27 to date. In the week ending 1 February 2026, 17,404 people in England had been waiting more than 62 days from an urgent referral, against 15,273 in the equivalent week before the pandemic. The plan also notes that cancer incidence is 15 percent higher than when the targets were last met, so restoring the standard is harder than restoring a number. The other three nations are not comparable and none is meeting its own standard either. Cancer Research UK's summary is the bluntest available: the 62-day standard has not been met since 2015 in England, since 2012 in Scotland, and never in Northern Ireland since it was introduced in 2008.

The 2025 clinical oncology census counts 1,138 whole time equivalent substantive consultant and specialist doctors in the NHS, of whom 1,049 are consultants, and puts the United Kingdom 234 whole time equivalents short. The shortfall was 8 percent in 2015 and 15 percent in 2024. It is worst where patients are poorest: small cancer centres average 26 percent against 13 at large ones, and centres in rural or more deprived areas 22 percent against 12 in urban or less deprived ones. By nation it is 17 percent in England, 17 in Wales, 18 in Scotland and 9 in Northern Ireland, with internal ranges that dwarf the national figures, from 11 percent in South Wales to 39 in North Wales and from 13 percent in South East Scotland to 21 in the north. Demand is outgrowing supply, radiotherapy activity at 4 percent and systemic therapy at 5.2 percent a year against workforce growth of 3.6 percent; one consultant in five is due to retire by 2030; and the share of centres reporting recruitment freezes more than doubled in a year, from 23 percent in 2024 to 51 percent in 2025. Radiology is worse in absolute terms: a 32 percent shortfall, 2,313 whole time equivalents, the largest recorded since at least 2019, ranging from 22 percent in London to 43 in the North East and from 16 percent in South East Scotland to 50 in the north of Scotland. The United Kingdom has 10.3 clinical radiologists per 100,000 people against an OECD average of 12.8 and a European Union average of 12.7, and only London exceeds the OECD figure. In 2025 the NHS spent 362 million pounds on outsourcing, insourcing and locum reporting, more than twice the 2021 figure and, by the college's arithmetic, enough to pay over 3,000 consultant radiologists; over a million diagnostic imaging studies in 2024/25 were not reported within the 28-day target.

OECD figures put United Kingdom health spending at 11.1 percent of GDP in 2024, eighth highest of 50 countries, and at 7,008 US dollars per person at purchasing power parity, sixteenth of 49 and below the western European average. The gap is in capital, not revenue: the King's Fund's 2023 comparison of 19 countries concluded that "the UK lags behind other countries in its capital investment, and has substantially fewer key physical resources than many of its peers, including CT and MRI scanners and hospital beds", and Lord Darzi's 2024 investigation put a number on it, that there would have been 27 billion pounds more capital investment in the 2010s had the UK matched the EU15, and 46 billion more had it matched the predominantly English-speaking countries. Darzi's own words on the consequence for cancer: "Despite the first clinical use of MRI taking place in an NHS hospital, the health service has far fewer MRI and CT scanners than comparable countries. Moreover, many of the machines are old." The Swedish Institute for Health Economics estimates the direct costs of cancer at 5.3 percent of United Kingdom health expenditure in 2023, or 219 euros per person at purchasing power parity, against 6.6 percent and 260 euros across Europe, 7.7 percent in both Germany and France. Research money is going the same way: the UK Health Research Analysis puts cancer research funding at 469.3 million pounds in 2022, 68.5 percent of it from charities, but its share of total UK health research funding has fallen from 20.3 percent in 2004/05 to 16.8 percent, a real-terms fall of 54 million pounds since 2018. The body that used to publish that map, the National Cancer Research Institute, closed in June 2023 after 22 years, was removed from the charity register on 14 August 2026, and its website no longer resolves; no successor has been named, and the 2026 National Cancer Plan does not mention it.

Lord O'Shaughnessy's review of commercial clinical trials, published in February 2023, found the United Kingdom ranked fourth in the world for phase 1 trials initiated in 2021 but tenth for phase 3, with 394 trials initiated against 471 in Spain, over 1,110 in China and nearly 2,000 in the United States, and recorded that the number of participants in NIHR-supported commercial research had fallen from over 50,000 in 2017/18 to just over 28,000 in 2021/22, a drop of 44 percent. The government committed up to 121 million pounds over three years in response. Recruitment has partly recovered, from 2,907 UK patients in a 25-company commercial subset in 2020 to 8,865 in 2023, and the UK's share of that subset from 3.0 percent in 2020 to 2.7 percent in 2023, fifth of ten; but the set-up time went the other way in every single year. The 2026 National Cancer Plan responds with a Cancer Trials Accelerator Programme and a pledge to cut trial set-up from over 250 days to 150, and records the patient-facing consequence of the present state: the 2024 national Cancer Patient Experience Survey found that fewer than half of respondents were offered the chance to take part in a trial at all.